Biophan Technologies, Inc. Biophans Patented Innovations Improve Medical Devices 2005 Money Show Michael Weiner, CEO.

Biophan Technologies, Inc.

Biophan’s Patented Innovations Improve Medical Devices  

2005 Money Show Michael Weiner, CEO

Biophan Technologies, Inc. (OTCBB: BIPH)

MEDICAL INNOVATION

The United States and most modern countries place a very high value on medical innovation

Once approved in the market, a medical innovation can generate significant wealth for the inventors and for the shareholders of the company(s) bringing the innovation to market

Over the past fifty years, medical innovations have changed the quality of life immensely, and made many large, and small, fortunes

Biophan Technologies, Inc. (OTCBB: BIPH)

PATENTS AND MONEY

U.S. Patents are one of the most potentially valuable financial instruments in the world

Once issued, they provide “the exclusive right to make, use, or sell,” the invention within the United States of America

The “claims” are where the true value lies One claim can be worth as much as $1 billion

(Polaroid vs. Kodak)

Biophan Technologies, Inc. (OTCBB: BIPH)

Enhancements

Once a product is on the market, another series of innovations and enhancements to the core device can create significant additional wealth

Some examples: “demand” pacing enhancement over pacemakers The implantable defibrillator enhancement Communicating pacemakers Implantable insulin pumps Hundreds more, worth BILLION$

Biophan Technologies, Inc. (OTCBB: BIPH)

BIOPHAN’s BUSINESS

Founded with pacemaker inventor Wilson Greatbatch, to make pacemakers safe for use with MRI

Expanded to include $12 billion worth of medical devices that ship with one problem, or another

Problems had not been solved by the medical device manufacturers

Finding, and patenting, a solution, would help patients, and help manufacturers offer a better device

That was the founding idea behind Biophan Without a strong U.S. Patent system, there would be

little incentive to invest money on solutions like this

Biophan Technologies, Inc. (OTCBB: BIPH)

INNOVATIONS IN INNOVATION

Biophan invests shareholder dollars… To discover, patent, and implement Valuable enhancements to multi-billion dollar

device markets Where the resulting innovation can make a major

shift in marketshare, among major industry players, in major industries

Biophan holds 36 issued US patents, and has 72 more pending; plus many international patents

Biophan Technologies, Inc. (OTCBB: BIPH)

Management

Stu MacDonald, VP R&D – formerly VP R&D at J&J division, with a 400 person organization

Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division

John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI)

Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA in public and private firms

Michael Friebe, Ph.D., MRI Scientist & Entrepreneur Andreas Melzer, MD, renowned medical innovator

Biophan Technologies, Inc. (OTCBB: BIPH)

Biophan’s Mission

Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: Guidewires, catheters, endoscopes, biopsy needles Pacemakers, defibrillators, neurostimulators, drug

pumps (safety issues, also imaging issues), pain control devices

Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics

Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.

Biophan Technologies, Inc. (OTCBB: BIPH)

Biophan’s Solutions

MRI Safety: (many products contraindicated) RF filter from Johns Hopkins (heating) “Anti-Antenna” lead design (heating & induced voltages) MRI Safe non-magnetic motor

Nanomagnetic particle technologies Minimize image artifacts Makes catheters, guidewires, stents, etc visible under MRI Contrast agents Drug Delivery

Biophan Technologies, Inc. (OTCBB: BIPH)

PROTECTED, PROTECTED!

Technologies covered by 114 U.S. Patents

36 ISSUED 72 pending or allowed

Owned by Biophan or licensed exclusively to Biophan for the medical market

Plus many International patents

MRI Device Imaging

SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.

1 2 3

Biophan’s thin-film

nanomagnetic particle

coating technology

provides a controllable,

“magnetic” signal

capable of creating an

image of the coated

device.

#3 is uncoated.

Biophan Technologies, Inc. (OTCBB: BIPH)

Making Stents Imageable

Seeing blockage of stents has required an invasive procedure

Stents imageable under MRI would be competitively advantaged

Nanoset has a nanomagnetic particle, thin film coating

AMRIS, now Biophan-Europe, has a “retrofit” solution

Both solutions are PATENTED!

Biophan Technologies, Inc. (OTCBB: BIPH)

1.5 Tesla MRI Artifacts of Current Stents

Expanded

StentsOriginal size

Crimped

Stents

Cobalt

316L stainless steel

With existing stent

technology, no useful

images can be obtained from within

common stents using

MRI.

Imaging of In-Stent Blood Clots Using Biophan Resonator Technology

1 Tesla Philips NT, head coil, TR=300ms, TE=6ms, FA=40°,

transversal

Cross Sectional Schematic of Stent with blood clot

Video

Biophan’s technology enables imaging of the blood clot within the stent

Resonant Stent Blood Clot

Biophan Technologies, Inc. (OTCBB: BIPH)

Implications

Impact the $5+ billion stent market Help manufacturers make pacemakers,

defibrillators, and neurostimulators safe, and imageable – competitive advantage to our licensees

Make guidewires, catheters, endoscopes, and biopsy needles safe and image compatible

Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)

Biophan Technologies, Inc. (OTCBB: BIPH)

Biothermal Battery

Goal: To provide a long-lived electrical power system for implanted medical devices Powered by body heat differential.

Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets

Sold to same customers who need MRI safety Nanomaterials brings this capability within striking

distance. We hold issued and pending patents

Biophan Technologies, Inc. (OTCBB: BIPH)

Agreement with NASA

Announced on August 17th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery NASA wants technology for their long duration

manned MARS mission for biosensing and miniature therapeutic devices

Biophan gets commercial rights to jointly developed and NASA developed technology

Nanotechnology and materials science advances makes the biothermal battery possible

Non-Magnetic MRI-Safe and

Imageable Greater efficiency Enables precision

20 nm movements Ideal for drug

pumps, cryogenic applications, implantables

Biophan holds worldwide medical distribution rights, + equity

Biophan Technologies, Inc. (OTCBB: BIPH)

Substrate

Polymer Coating

Nanomagnetic layer

Con

trol

led

Mag

netic

Fie

ldDrug bound to NMP carrier

Con

trol

led

Mag

netic

Fie

ld A

Con

trol

led

Mag

netic

Fie

ld B

Particle type ADrug AParticle type BDrug B

Surface Elution on Demand

Biophan Technologies, Inc. (OTCBB: BIPH)

Reloading Drug Eluting Coatings

Substrate

Polymer Coating

Concentration G

radient

Controlled

Magnetic F

ield

Drug Molecules

Drug bound to NMP carrier

Nanomagnetic layer

Biophan Technologies, Inc. (OTCBB: BIPH)

Guided Drug Delivery

Solid tumor

Apply magnetic field to concentrate particles

Modulate field to release drug from particles

Inject NMPs IV,NMP will circulate through the blood stream

Other options for targeting:1 - Direct injection into tumor site2 - Coating NMP with antibodies to target tumor

Biophan Technologies, Inc. (OTCBB: BIPH)

Markets

Medical devices (safe &/or image): $12 billion Battery: $500 million Contrast Agents: $800 million Drug Pumps: $1 billion Drug Delivery: $40 billion Once a deal is underway, patents and annuity

streams can last a long time; We anticipate money on signing, in development;

plus milestones, royalties, high margin components

Biophan Technologies, Inc. (OTCBB: BIPH)

Business Model

Offering our customers competitive advantage Through proprietary solutions that can gain

marketshare for them FDA approval is pursued by the customer Marketing and distribution of the final device is

their responsibility We sell high margin components and develop

annuities for our shareholders

Biophan Technologies, Inc. (OTCBB: BIPH)

Relationship With Boston Scientific

Joint development agreement, originally entered into November, 2003

Recently moved to second and third phase, and has expanded to multiple products

Reached agreement on term sheet, working on final contract phase

Biophan Technologies, Inc. (OTCBB: BIPH)

Summary Financial Information

Share Price (05-9-05): $2.36 52-Week High: $3.50 52 Week Low: $0.46 Shares Outstanding: 74 million Float: 58 million Market Cap: $176 million Average Daily Volume: 1,218,772

Biophan Technologies, Inc. (OTCBB: BIPH)

BIOPHAN (OTCBB: BIPH)

Biophan Technologies, Inc. (OTCBB: BIPH)

Biophan (OTC: BIPH)

We don’t make medical devices; We make them safe, and imageable, for MRI

And other competitive advantages for our customers

Four of our six technologies are based on nanotechnology

WWW.BIOPHAN.COM